SynthesisFrontiers in oncology2025
Effect of locoregional surgery in primary tumors on overall survival in patients with
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in locoregional surgical treatment ofFrontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Due to the controversy in the therapeutic effect of locoregional surgery in primary tumors for patients with de novo stage IV breast cancer, the aim of this study was to evaluate the effect of locoregional surgery on overall survival in patients with de novo stage IV breast cancer. Methods: A computer-based search of PUBMED, Embase, and American Society of Oncology (ASCO) annual meetings abstracts was conducted to identify the prospective trials of the combination of locoregional surgery in primary tumors and systemic therapy in comparison with standard systemic therapy alone for patients with de novo stage IV breast cancer. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated by universal inverse variance and combined across articles. Random-effects model and subgroup analyses were performed to ascertain the origin of this heterogeneity. Results: A total of 2029 patients from 8 studies were included, with 1014 patients (49.98%) underwent locoregional surgery in primary tumors (surgery group) and 1015 ones (50.02%) with standard systemic therapy alone (no surgery group). Compared to patients in the no surgery group, participants with ER/PR positive breast cancer in the surgery group had improved overall survival (OS) (HR=0.77, 95%CI 0.55-0.93, P=0.01), and improved locoregional progression-free survival (HR=0.36, 95%CI 0.14-0.95, P=0.04) for all participants in the surgery group. And patients with bone-only metastases in the surgery group had insignificantly favorable OS than those in no surgery group (HR=0.70, 95%CI, 0.47-1.04, P=0.08). Conclusion: Our study demonstrated that locoregional surgery in primary tumors was associated with improved OS for participants with ER/PR positive
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.